Worldwide beliefs among pregnant women on SARS-CoV-2 vaccine: a systematic review

Carbone, Luigi; Girolamo, Raffaella Di; Mappa, Ilenia; Saccone, Gabriele; Raffone, Antonio; Mascio, Daniele Di; Vivo, Valentino De; D’Antonio, F.; Guida, Maurizio; Rizzo, Giuseppe; Maruotti, Giuseppe Maria

doi:10.1016/j.ejogrb.2021.12.003

Cited by 36 publications

(33 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This prevalence is considerably lower than that of pregnant women who expressed the intention to be vaccinated against COVID-19. In particular, two meta-analyses [ 36 , 37 ] found that the global prevalence of pregnant women accepting the COVID-19 vaccine was about 49–54%. Moreover, in a survey with 5282 pregnant women from 16 countries, 52% of them indicated an intention to receive a COVID-19 vaccine [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Uptake of COVID-19 Vaccines among Pregnant Women: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Mass vaccination against COVID-19 is essential to control the pandemic. COVID-19 vaccines are now recommended during pregnancy to prevent adverse outcomes. With this review, we aimed to evaluate the evidence in the literature regarding the uptake of COVID-19 vaccinations among pregnant women. A comprehensive search was performed in PubMed, Medline, Scopus, ProQuest, Web of Science, CINAHL, and medRxiv from inception to 23 March 2022. We performed a meta-analysis to estimate the overall proportion of pregnant women vaccinated against COVID-19. We found 11 studies including 703,004 pregnant women. The overall proportion of pregnant women vaccinated against COVID-19 was 27.5% (95% CI: 18.8–37.0%). Predictors of COVID-19 vaccination uptake were older age, ethnicity, race, trust in COVID-19 vaccines, and fear of COVID-19 during pregnancy. Mistrust in the government, diagnosis of COVID-19 during pregnancy, and fears about the safety and side effects of COVID-19 vaccines were reasons for declining vaccination. The global COVID-19 vaccination prevalence in pregnant women is low. A large gap exists in the literature on the factors influencing the decision of pregnant women to be vaccinated against COVID-19. Targeted information campaigns are essential to increase vaccine literacy among pregnant women.

show abstract

Section: Discussionmentioning

confidence: 99%

Uptake of COVID-19 Vaccines among Pregnant Women: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Such recommendations are especially important considering a low acceptance rate for vaccination in pregnancy. A recent systematic review of 15 studies has shown that only 49% of pregnant women are willing to be vaccinated during pregnancy [ 21 ]. However, large trials evaluating the clinical efficacy of the third dose of the vaccine in pregnancy are still needed.…”

Section: Discussionmentioning

confidence: 99%

Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy

Toussia-Cohen

Yinon

Peretz-Machluf

et al. 2022

JCM

View full text Add to dashboard Cite

(1) Background: The adverse-effect profile and short-term obstetric and neonatal outcomes among pregnant women who were vaccinated with the BNT162b2 vaccine at any stage of pregnancy do not indicate any safety concerns. The vaccine is effective in generating a humoral immune response in pregnant women. (2) Objective: To determine the vaccine-induced immunity and adverse events associated with the third (booster) dose of the BNT162b2 vaccine compared to the first and second dose of the vaccine among pregnant women. (3) Study design: A prospective cohort study in a tertiary referral center comparing pregnant women who were vaccinated by the first and second dose of the BNT162b2 (Pfizer/BioNTech) vaccine to pregnant women vaccinated by a third (booster) dose, between January and November 2021. A digital questionnaire regarding adverse events was filled by both groups 2–4 weeks after vaccination. Blood samples were collected and tested for SARS-COV-2 IgG antibodies 28–32 days after the administration of the second or third BNT162b2 dose. (4) Results: Seventy-eight pregnant women who received the first and second doses of the vaccine were compared to eighty-four pregnant women who received the third dose of the vaccine. In terms of adverse events following vaccination, local rash/pain/swelling (93.6% vs. 72.6%, p < 0.001) was significantly less common after the third vaccination compared to after the second vaccination. Other adverse events, including early obstetric complications, did not differ between the two groups. SARS-CoV-2 IgG serum levels 28–32 days after the vaccination were significantly higher after the third vaccination compared to the second vaccination (1333.75 vs. 2177.93, respectively, p < 0.001). (5) Conclusion: This study confirms the safety regarding early adverse events and immunogenicity, and the lack of early obstetric complications of the BNT162b2 second- and third-dose vaccine in pregnant women. The third (booster) dose is effective in generating a stronger humoral immune response in pregnant women compared with the second dose.

show abstract

“…This evidence raised the question of the importance of COVID-19 vaccine in pregnant women even in absence of level-1 data on safety of vaccine in this population [65][66][67]. However, since the introduction of vaccinal programs against SARS-CoV-2 infection, pregnant women demonstrated that the anxiety of contracting the infection was not higher than the anxiety of possible adverse events linked to the novel mRNA-based vaccines, with low percentages of acceptance worldwide [68][69][70][71][72][73][74][75][76][77][78][79][80][81][82]. Indeed, so far reassuring data have been released and published on the importance of vaccine against SARS-CoV-2 during pregnancy, given that antibodies generate a robust humoral immunity in pregnant and lactating women and were also transferred to fetus and neonates through cord blood and breast milk [83][84][85].…”

Section: F O R P U B L I C a T I O Nmentioning

confidence: 99%

Maternal and Perinatal Outcomes of Pregnant Women with SARS-CoV-2 infection: a single center experience

Guida¹,

Carbone²,

Ferrara³

et al. 2022

It Journ Gyn Obs

View full text Add to dashboard Cite

Background:The aim of this study was to evaluate maternal and perinatal outcomes of pregnant women affected by COVID-19 during the first pandemic wave in a third level university hospital of southern Italy. Methods:This was a single-center, cohort study on SARS-CoV-2 in pregnancy. Pregnant women with laboratory-confirmed SARS-COV-2 from August 1, 2020 to January 1, 2021 from University of Naples Federico II were included in the study. A confirmed case of COVID-19 was defined as a positive result on real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. The primary outcome was the incidence preterm birth.Results: 249 singleton pregnancies, positive to SARS-COV-2 at RT-PCR nasal and pharyngeal swab, were included in the study. Mean gestational age at diagnosis was 31.0 ± 6.7 weeks, with 2.4% of women being diagnosed in the first, 14.1% in the second and 83.5% in the third trimester of pregnancy. The vast majority of the women received therapy with low molecular weight heparin (88.8%). 47 women (18.9%) required oxygen therapy. The rate of admission to the maternal intensive care unit was 2.8%. There was one case of maternal death, accounting for a maternal mortality rate of 0.4%. Out of the 249 ended pregnancies, we reported two spontaneous abortions and two stillbirths. Among the 245 live-born babies, no neonatal deaths were recorded. All babies were tested negative at RT-PCR nasal and pharyngeal swab. The incidence of preterm delivery before 37 weeks was 10%.Conclusion: SARS-COV-2 infection in pregnant women during the first pandemic wave in the South of Italy was associated with relative low rates of maternal and perinatal adverse outcome.

show abstract

Worldwide beliefs among pregnant women on SARS-CoV-2 vaccine: a systematic review

Cited by 36 publications

References 66 publications

Uptake of COVID-19 Vaccines among Pregnant Women: A Systematic Review and Meta-Analysis

Uptake of COVID-19 Vaccines among Pregnant Women: A Systematic Review and Meta-Analysis

Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy

Maternal and Perinatal Outcomes of Pregnant Women with SARS-CoV-2 infection: a single center experience

Contact Info

Product

Resources

About